Yanlin Bian

Shanghai, 200240, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

A CXCR4/PD-L1 Bispecific Nanobody Engineered for Tumor Microenvironment Retention Mediates Sustained Synergy with Chemotherapy via Remodeling Immunity in TNBC.

A CXCR4/PD-L1 Bispecific Nanobody Engineered for Tumor Microenvironment Retention Mediates Sustained Synergy with Chemotherapy via Remodeling Immunity in TNBC.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 23, 2026

Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering.

Rapid restoration of potent neutralization activity against the latest Omicron variant JN.1 via AI rational design and antibody engineering.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 05, 2025

The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer.

The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 26, 2024

ABTrans: A Transformer-based Model for Predicting Interaction between Anti-Aβ Antibodies and Peptides.

ABTrans: A Transformer-based Model for Predicting Interaction between Anti-Aβ Antibodies and Peptides.

Journal: Interdisciplinary sciences, computational life sciences

Published: March 16, 2024

Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.

Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 31, 2023

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies.

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies.

Journal: Heliyon

Published: December 31, 2022

Neutralization of SARS-CoV-2 infection by antibodies targeting diverse epitopes.

Neutralization of SARS-CoV-2 infection by antibodies targeting diverse epitopes.

Journal: Genes & diseases

Published: November 11, 2022

Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix.

Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix.

Journal: Virologica Sinica

Published: August 23, 2022

The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer.

The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer.

Journal: Biomedicines

Published: June 23, 2022

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD.

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD.

Journal: Cell discovery

Published: October 27, 2021

A Rational Designed Novel Bispecific Antibody for the Treatment of GBM.

A Rational Designed Novel Bispecific Antibody for the Treatment of GBM.

Journal: Biomedicines

Published: April 03, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026